|
Early discontinuation to adjuvant endocrine therapy in the ECOG-ACRIN TAILORx Trial. |
|
|
Employment - Vibrent Health (I) |
|
|
Research Funding - Abbvie; Agios; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Genomic Health; Genzyme; GlaxoSmithKline; Janssen-Ortho; Merck Sharp & Dohme; Novartis; Onyx; Pfizer; Sanofi; Sequenta; Syndax; Takeda |
|
|
Stock and Other Ownership Interests - Metastat |
Consulting or Advisory Role - Adgero Biopharmaceuticals; AstraZeneca; Cardinal Health; Celgene; Celldex; Genentech/Roche; Juno Therapeutics; Lilly; Merrimack; Novartis; Pfizer; Prescient Therapeutics |
Research Funding - Deciphera (Inst); Genentech/Roche (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Novartis (Inst); Prescient Therapeutics (Inst); Radius Health (Inst) |
Travel, Accommodations, Expenses - Adgero Biopharmaceuticals; AstraZeneca; Menarini Silicon Biosystems; Myriad Genetics; Pfizer; Roche/Genentech |
|
|
Travel, Accommodations, Expenses - GE Healthcare |
Other Relationship - Journal of the American College of Radiology. (Inst) |
|
|
Research Funding - TailorMed |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Genomic Health |
|
|
Leadership - Syndax; Tessa Therapeutics |
Stock and Other Ownership Interests - Syndax; Tessa Therapeutics |
Consulting or Advisory Role - Radius Health; Symphogen; Synaffix; Syndax; Taiho Pharmaceutical; Verseau Therapeutics |
Research Funding - Genentech/Roche (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Radius Health; Tessa Therapeutics; Verseau Therapeutics |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene |
Travel, Accommodations, Expenses - Celgene |